Arch Oncology

Arch Oncology

Founded 2006

Brisbane, United States 7 employees Series C Total: $250.40M Biotechnology, Health and Wellness

Arch Oncology is a biotechnology company founded in 2006 and based in the United States. The company is primarily focused on developing groundbreaking antibody therapies for the treatment of solid tumors and hematologic malignancies. Their lead product candidate AO-176 is currently in Phase 1/2 clinical trials for the treatment of select solid tumors and multiple myeloma, both as monotherapy and in combination with standard therapies. One of the key differentiators of Arch Oncology's next-generation anti-CD47 antibodies, particularly AO-176, is its ability to block the "don’t eat me" signal for macrophages, inducing Immunogenic Cell Death in addition to directly killing tumor cells. Importantly, AO-176 binds preferentially to CD47 on tumor cells and displays increased efficacy in low pH conditions, such as the tumor microenvironment. Arch Oncology recently received a significant $105.00M Series C investment from a consortium of notable investors including 3x5 Partners, RiverVest, Adage Capital Management, Avego Bioscience Capital, Broadfin Capital, Cowen Digital, Lightchain, Roche Venture Fund, FMB Research, and Eventide, on 27th April 2021. The company's headquarters are located in Brisbane, CA, known for its status as a biotechnology innovation hub, with its scientific research laboratory based in St. Louis, MO, the home of the famous Gateway Arch.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	$105.00M	10	RiverVest, Adage Capital Management +8	27 Apr 2021
Series B	$50.00M	-		25 Mar 2019
Series A	$86.00M	-		16 Aug 2016
Venture Round	$8.13M	-		10 Aug 2015
Venture Round	$1.27M	-		12 Feb 2015

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

$105.00M

RiverVest, Adage Capital Management +8

27 Apr 2021

Series B

$50.00M

25 Mar 2019

Series A

$86.00M

16 Aug 2016

Venture Round

$8.13M

10 Aug 2015

Venture Round

$1.27M

12 Feb 2015

FAQ About Arch Oncology

Arch Oncology, Inc. is a clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies. Our lead product candidate AO-176 is in Phase 1/2 clinical trials for t...

Arch Oncology was founded in 2006.

Arch Oncology is headquartered in Brisbane, United States.

Arch Oncology operates in Biotechnology and Health and Wellness. Its work centres on immuno-oncology, antibody therapies, clinical-stage and Phase 1/2 trials.

Arch Oncology has approximately 7 employees.

Arch Oncology has completed 5 funding rounds, raising a total of $250.40M. The latest funding stage is Series C.

Top alternatives and competitors to Arch Oncology include Tarveda Therapeutics, ImmunoBiochem Corporation, Acepodia, Harpoon Therapeutics, Silverback Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Arch Oncology and Tarveda Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Arch Oncology

Funding Rounds & Investors (5)

Arch Oncology Alternatives & Competitors

FAQ About Arch Oncology